<?xml version="1.0" encoding="iso-8859-1"?>
		<rss version="2.0" >
        <channel>
        <title>antaranusa.com | berita nusantara internasional</title>
        <link>https://antaranusa.com/</link>
        <description>antaranusa situs</description>
        <language>en-us</language>
        <pubDate>Fri, 04 Sep 2026 07:26:48 +0700</pubDate>
        <lastBuildDate>Fri, 04 Sep 2026 07:26:48 +0700</lastBuildDate>
        <generator>antaranusa.com | berita nusantara internasional RSS Generator</generator>
        <managingEditor>antaranusa123@gmail.com</managingEditor>
        <webMaster>arie.vcr@gmail.com</webMaster>
		<image>
		<url>https://antaranusa.com/icon.gif</url>
		<title>antaranusa.com | berita nusantara internasional</title>
		<link>https://antaranusa.com/</link>
		<description>Fasilitas RSS dari antaranusa</description>
		</image>
<item>
<title>Patton and alfanar Partner to Accelerate Secure Digital Transformation of Saudi Power Infrastructure</title>
<link>https://antaranusa.com/antaranusa-business/Patton-and-alfanar-Partner-to-Accelerate-Secure-Digital-Transformation-of-Saudi-Power-Infrastructure</link>
<description><![CDATA[<img src=https://antaranusa.com/photo/berita/dir092026/3453_Patton-and-alfanar-Partner-to-Accelerate-Secure-Digital-Transformation-of-Saudi-Power-Infrastructure.jpg border=0 hspace=5 align=left width=350 />  <div><br></div><div><div>Strategic agreement pairs Patton&#039;s industrial networking and cybersecurity technology with alfanar&#039;s energy-infrastructure expertise to modernize smart-grid and substation operations across Saudi Arabia</div><div><br></div><div>GAITHERSBURG, Md. and PARIS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Patton LLC-a U.S.-based developer of industrial networking, connectivity, and cybersecurity technologies-today announced a strategic cooperation agreement with alfanar-a leading multinational provider of energy, infrastructure, and digital solutions.</div><div><br></div><div>The agreement establishes a framework for collaboration focused on modernizing Operational Technology (OT) and IT networks supporting electrical substations, smart-grid infrastructure, and critical energy operations throughout Saudi Arabia.</div><div><br></div><div>Delivered through alfanar Digital Solutions (ADS) and alfanar eDAS, the partnership covers industrial automation, smart-grid modernization, digital substations, and cybersecurity for critical infrastructure-integrating IIoT architectures aligned with Industry 4.0 standards, secure OT networking, grid cybersecurity, network segmentation, SCADA policy enforcement, and resilient substation automation.</div><div><br></div><div>Key Patton Technologies</div><div><br></div><div>ConnectIT CIT-SFP - a compact serial-to-IP platform that lets legacy RTUs, SCADA systems, protection relays, and Intelligent Electronic Devices (IEDs) integrate with modern Ethernet/IP networks without replacing installed assets</div><div>CopperLink CL-SFP - extends Ethernet connectivity over existing copper infrastructure to accelerate IP-based communications</div><div>FiberPlex SFX Data Diode SFP modules - hardware-enforced, unidirectional cybersecurity solutions that enable secure data transfer from operational systems to monitoring platforms while blocking unauthorized inbound access.</div><div><br></div><div>The agreement also gives alfanar access to Patton&#039;s Special Projects Group, contract development, engineering, and manufacturing services for customized initiatives that support the Kingdom&#039;s evolving electrical infrastructure needs.</div><div><br></div><div>"Saudi Arabia continues to make significant investments in modernizing its energy infrastructure and advancing its Vision 2030 objectives," said Burton Patton, Chief Revenue Officer of Patton LLC. "We are proud to cooperate with alfanar, contributing our products, IP competency, and engineering capabilities to support secure digital transformation across the Kingdom&#039;s energy sectors."</div><div><br></div><div>"This cooperation agreement brings together complementary capabilities essential to the future of intelligent energy systems," said Chadi Iskandar, Vice President, eDAS, alfanar. "Together, we will help customers accelerate deployment of smart-grid, automation, and digital substation architectures while maintaining the highest standards of security and reliability."</div><div><br></div><div>The announcement comes amid growing US-Saudi cooperation, including the recent US-Saudi 123 Agreement on Peaceful Nuclear Cooperation. While unrelated to nuclear technology, the partnership reflects the broader strength of bilateral commercial ties.</div><div><br></div><div>Together, Patton and alfanar will pursue opportunities that support next-generation utility infrastructure, intelligent substations, secure OT networking, and smart transmission and distribution initiatives that advance Saudi Vision 2030.</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div></div> ]]></description>
<pubDate>Fri, 04 Sep 2026 07:19:00 +0700</pubDate>
</item>
<item>
<title>nCino to Participate in Upcoming Investor Event </title>
<link>https://antaranusa.com/antaranusa-business/nCino-to-Participate-in-Upcoming-Investor-Event--2</link>
<description><![CDATA[<img src=https://antaranusa.com/photo/berita/dir092026/9266_nCino-to-Participate-in-Upcoming-Investor-Event-.jpg border=0 hspace=5 align=left width=350 />  <div><br></div><div><div>WILMINGTON, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- nCino, Inc. (NASDAQ: NCNO), the platform for agentic AI banking, today announced its participation in the following investor conference:</div><div><br></div><div>Piper Sandler Growth Frontiers Conference</div><div>Presentation: Wednesday, September 16, 2026, at 11:30 a.m. CT (12:30 p.m. ET)</div><div><br></div><div>The live webcast, as well as a replay from the event, will be available on the Company Investor relations website at https://investor.ncino.com/news-events/events-presentations.</div><div><br></div><div>About nCino</div><div>nCino (NASDAQ: NCNO) is the platform for agentic AI banking. With over 2,700 customers worldwide - including community banks, credit unions, independent mortgage banks, and the largest financial entities globally - nCino offers a trusted, agentic platform purpose-built for financial services and regulated industries.</div><div><br></div><div>By deploying AI agents alongside human teams, nCino&#039;s dual workforce enables institutions to eliminate inefficiencies, sharpen decision-making and deliver better outcomes for the customers they serve. For more information, visit www.ncino.com.</div><div><br></div><div>INVESTOR CONTACT</div><div>investor@ncino.com</div><div>&nbsp;</div><div>MEDIA CONTACT</div><div>press@ncino.com</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div></div> ]]></description>
<pubDate>Fri, 04 Sep 2026 07:09:00 +0700</pubDate>
</item>
<item>
<title>Tektronix introduces PCIe 7.0 transmitter and receiver test software for 128 GT/s PAM4 designs</title>
<link>https://antaranusa.com/antaranusa-business/Tektronix-introduces-PCIe-7-0-transmitter-and-receiver-test-software-for-128-GT-s-PAM4-designs</link>
<description><![CDATA[<img src=https://antaranusa.com/photo/berita/dir092026/7984_Tektronix-introduces-PCIe-7-0-transmitter-and-receiver-test-software-for-128-GT-s-PAM4-designs.jpg border=0 hspace=5 align=left width=350 />  <div><br></div><div><div>New software helps engineers isolate 128 GT/s signal problems earlier and validate the high-bandwidth connections required by AI and high-performance computing systems</div><div><br></div><div>BEAVERTON, Ore, Sept. 02, 2026 (GLOBE NEWSWIRE) --&nbsp;Tektronix today introduced new automated transmitter and receiver test software for PCI Express (PCIe) 7.0 Base designs operating at 128 GT/s.</div><div><br></div><div>The new TekExpress PCIe 7.0 Transmitter Test Application and expanded PCIe 7.0 capabilities in TekRxTest, Tektronix&#039;s receiver test software, help engineers automate transmitter measurements, calibrate precisely stressed receiver signals and validate designs against PCIe 7.0 Base Specification requirements.&nbsp;</div><div><br></div><div>Tektronix also expanded its PAMJET Transmitter Analysis Software with advanced PCIe 7.0 capabilities. The software helps engineers identify sources of noise, jitter and other complex signal-integrity problems that standard measurements alone may not explain.&nbsp;&nbsp;</div><div><br></div><div>As AI systems scale, moving data efficiently among processors, accelerators, memory, storage and networking becomes as important as adding compute capacity. PCIe provides the high-bandwidth connections among those components, making its continued advancement essential to AI, machine learning, high-performance computing and data center systems.&nbsp;</div><div><br></div><div>PCIe 7.0 doubles the PCIe 6.0 data rate to 128 GT/s and supports up to 512 GB/s of bidirectional bandwidth over 16 lanes. Those gains leave far less room for electrical error. At 128 GT/s, channel loss, crosstalk, power delivery noise and jitter become more difficult to isolate, while measurement-system effects can obscure a device&#039;s true performance.&nbsp;&nbsp;</div><div><br></div><div>For semiconductor and system developers, these challenges can slow first-silicon bring-up, complicate correlation across engineering teams and allow problems to remain hidden until later development stages. Engineers need repeatable ways to evaluate transmitter behavior, create accurate receiver test conditions and move quickly from a failed measurement to its underlying cause.&nbsp;</div><div><br></div><div>"Customers developing PCIe 7.0 designs need confidence that their measurements reflect the device, not the test environment," said Daryl Ellis, Vice President and General Manager of Tektronix&#039;s Signal Acquisition and Analysis Portfolio. "We combine precise measurement, guided software and direct application expertise to help them solve problems earlier and move PCIe 7.0 designs forward."&nbsp;</div><div><br></div><div>Find problems earlier at 128 GT/s&nbsp;</div><div><br></div><div>The new capabilities address three critical stages in PCIe 7.0 electrical validation. By combining TekExpress, TekRxTest and PAMJET with 70 GHz DPO70000SX ATI performance oscilloscope and the Anritsu MP1900A Signal Quality Analyzer-R, engineering teams gain a coordinated PCIe 7.0 Base test solution for transmitter measurement, receiver stress calibration and validation, and root-cause PAM4 analysis.&nbsp;</div><div><br></div><div>Automate transmitter testing: The TekExpress PCIe 7.0 Transmitter Test Application automates setup, waveform acquisition, analysis and reporting for transmitter measurements defined in the PCIe 7.0 Base specification, including signal-to-noise-and-distortion ratio, ratio of level mismatch, jitter and transmitter preset equalization. Engineers can evaluate first silicon, compare presets and design revisions, and identify electrical problems before system integration.</div><div>Simplify receiver calibration and validation: TekRxTest controls the Tektronix oscilloscope and the Anritsu MP1900A through one guided workflow for TP3 and TP2 stressed-eye calibration, preset and continuous-time linear equalization (CTLE) optimization, and channel verification. The MP1900A provides the stressed signaling required for PCIe 7.0 receiver calibration and validation. Automated oscilloscope noise compensation supports accurate sinusoidal- and random-jitter calibration, helping engineering organizations create repeatable test conditions across teams and test environments.&nbsp;&nbsp;</div><div>Move from failure to root cause: Expanded PAMJET capabilities provide noise-aware measurements, clock recovery, correlated and composite eye views, analysis of individual PAM4 transitions and direct navigation to symbol-error events. These capabilities help engineers distinguish device behavior from channel and measurement system effects and expose problems that averaged or aggregate measurements can conceal.&nbsp;</div><div><br></div><div>Together, these capabilities help engineers validate chip-level designs against PCIe 7.0 Base electrical requirements, laying the groundwork for future CEM implementations and compliance testing. TekExpress and TekRxTest also support workflows for earlier PCIe generations, helping engineering teams retain familiar test processes as they validate backward compatibility and move toward PCIe 7.0.&nbsp;</div><div><br></div><div>Confidence as PCIe evolves&nbsp;</div><div><br></div><div>As customers adopt each PCIe generation, they must make critical design decisions while requirements, test methods and industry experience are still evolving. For generations of PCIe, Tektronix engineers have actively participated in PCI-SIG Work Groups and pathfinding efforts, applying that knowledge to the software, measurement methods and technical guidance customers use to evaluate designs before deployment.&nbsp;&nbsp;</div><div><br></div><div>Tektronix also supports PCI-SIG compliance workshops as a Gold Suite-approved test vendor for PCIe 5.0 and PCIe 6.0, helping engineers evaluate device interoperability and resolve problems early.&nbsp;&nbsp;</div><div><br></div><div>Availability&nbsp;</div><div><br></div><div>The TekExpress PCIe 7.0 Transmitter Test Application and expanded PCIe 7.0 capabilities in TekRxTest are available now. PAMJET Transmitter Analysis Software is purchased separately and is available now for compatible Tektronix high-performance oscilloscopes.&nbsp;&nbsp;</div><div><br></div><div>Learn more about Tektronix PCIe test solutions at tek.com/pci-express.</div><div><br></div><div># # #&nbsp;</div><div><br></div><div>About Tektronix&nbsp;</div><div><br></div><div>Tektronix is the partner engineers have trusted to measure, discover, and innovate for 80 years. Today we deliver test and measurement solutions that unite precision with simplicity, helping engineers accelerate breakthroughs that shape a better tomorrow. Learn more at tek.com/newsroom.&nbsp;</div><div><br></div><div>Tektronix is a registered trademark of Tektronix, Inc. All other trade names referenced are the service marks, trademarks, or registered trademarks of their respective companies.&nbsp;</div><div><br></div><div>SOURCE: Tektronix, Inc.&nbsp;</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div></div> ]]></description>
<pubDate>Fri, 04 Sep 2026 06:58:00 +0700</pubDate>
</item>
<item>
<title>Command Alkon Celebrates a Half-Century as the Operating Platform Behind the World&#039;s Heavy Building Materials</title>
<link>https://antaranusa.com/antaranusa-business/Command-Alkon-Celebrates-a-Half-Century-as-the-Operating-Platform-Behind-the-World--039-s-Heavy-Building-Materials</link>
<description><![CDATA[<img src=https://antaranusa.com/photo/berita/dir092026/4972_Command-Alkon-Celebrates-a-Half-Century-as-the-Operating-Platform-Behind-the-World--039-s-Heavy-Building-Materials.jpg border=0 hspace=5 align=left width=350 />  <div><br></div><div><div>From five employees and a single product in 1976 to a cloud platform running hundreds of thousands of dispatched loads a day worldwide, Command Alkon marks 50 years of building technology for today and for the future</div><div><br></div><div>HILLIARD, Ohio, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Today marks 50 years since Command Alkon, the leading software and solutions provider for the heavy building materials industry, opened its doors, and the company is marking the occasion by staying true to the idea that has guided it since 1976: that the heavy building materials industry deserves technology built for it, not adapted from somewhere else.</div><div><br></div><div>Half a century later, Command Alkon has grown to be the operating platform for more than 2,800 customers in over 80 countries, from single-plant independent producers to the largest multinational materials companies in the world. On any given day, Command Alkon systems are behind more than 690,000 dispatched loads, 60,000 tracked trucks, and 20,000 production installations running ready mix, aggregate, asphalt, and cement operations across the globe.</div><div><br></div><div>"This industry runs on precision," said Martin Willoughby, Chief Executive Officer of Command Alkon. "A truck has to arrive on time, a mix has to be right, a load has to get where it&#039;s going and there&#039;s no room to treat any of that as an afterthought. Producers build their operations around our technology because they need a partner who understands that."</div><div><br></div><div>The Discipline Behind 50 Years of Innovation</div><div><br></div><div>Command Alkon&#039;s story starts with two companies that arrived in the same industry from different directions. Command Data built accounting and dispatch systems for ready mix producers. The Alkon Corporation pioneered plant automation. Both companies were solving real problems for an industry that had outgrown manual processes and needed technology that could keep pace with its complexity. When the two merged in the early 2000s, they didn&#039;t just combine product lines - they built a company shaped by the realities of the plants, trucks, and jobsites it served, rather than by what off-the-shelf software could offer.</div><div><br></div><div>That refusal to generalize has defined every acquisition since. ConAd became the foundation of Command Alkon&#039;s ready mix quality control solution. JWS Corporation&#039;s Apex product line is one of the most widely used bulk materials scale-ticketing systems in the world. FiveCubits, Ruckit, Trimble Construction Logistics, Libra, Marcotte Systems, and Digital Fleet, each added value for production, logistics, and fleet connectivity, deepening the product portfolio and company capabilities.</div><div><br></div><div>In the late 2000s and mid-2010s, that same discipline drove Command Alkon&#039;s global expansion, transforming it into a truly international company now serving customers in more than 80 countries with localized expertise and 24/7 support.</div><div><br></div><div>Command Cloud and the Next Chapter</div><div><br></div><div>Introduced in early 2024, Command Cloud is where that focus comes together: a unified platform connecting production, dispatch, fleet, and financials. It is the culmination of years of deliberate investment in something the industry had never had before ? one platform, for every material, in one place.</div><div><br></div><div>Command Cloud is designed to grow with a producer rather than lock them in. Its API-open architecture and enterprise-grade security let producers connect the tools they already rely on, add new capabilities as they need them, and shape their own technology landscape instead of working around a rigid, one-size-fits-all system. Production, dispatch, and fleet all run from the same connected environment from quote-to-cash, in real time. Producers get a live picture of the operation rather than yesterday&#039;s reports - and the flexibility to scale that operation up without giving up security or reliability along the way.</div><div><br></div><div>"Generic platforms cannot replicate what we&#039;ve built," said Willoughby. "We know what a good pour looks like, what it takes to keep a fleet moving under real pressure, and what separates a plant that&#039;s actually running well from one that just looks like it is. That knowledge is baked into everything we&#039;ve built for the past 50 years, and it&#039;s not something anyone can shortcut."</div><div><br></div><div>What Comes Next</div><div><br></div><div>Command Alkon enters its second half-century with its sharpest strategic identity yet: a single platform, an AI roadmap built for real operational outcomes rather than features, and fifty years of domain expertise that is genuinely difficult to replicate. The company is also investing in the next generation of the industry&#039;s workforce - modern, mobile-first tools and accessible learning resources designed to reduce reliance on institutional knowledge and make heavy building materials careers more attractive to the people who will run this industry for the next fifty years.</div><div><br></div><div>"Fifty years ago, five people set out to build software that actually fits the industry they were serving," said Willoughby. "That instinct hasn&#039;t changed. What&#039;s changed is the scale at which we can deliver on it."</div><div><br></div><div>About Command Alkon</div><div><br></div><div>Command Alkon is the global leader in software and platform technology for the heavy building materials industry. Through Command Cloud, the company connects raw materials, production, dispatch, logistics, and financials in a single platform purpose-built for ready mix, asphalt, aggregate producers. With 50 years of industry expertise and a presence in more than 80 countries, Command Alkon powers mission-critical operations for thousands of producers worldwide, delivering real-time visibility, operational precision, and data-driven insights across the entire materials value chain.</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div></div> ]]></description>
<pubDate>Fri, 04 Sep 2026 06:53:00 +0700</pubDate>
</item>
<item>
<title>Donna Karan New York Unveils Its Fall 2026 Campaign Featuring Kendall Jenner</title>
<link>https://antaranusa.com/antaranusa-business/Donna-Karan-New-York-Unveils-Its-Fall-2026-Campaign-Featuring-Kendall-Jenner</link>
<description><![CDATA[<img src=https://antaranusa.com/photo/berita/dir092026/5070_Donna-Karan-New-York-Unveils-Its-Fall-2026-Campaign-Featuring-Kendall-Jenner.jpg border=0 hspace=5 align=left width=350 />  <div><br></div><div><div><div>Kendall Jenner in the Donna Karan New York Fall 2026 campaign, photographed by Mert Alas.</div><div><br></div></div><div>NEW YORK, NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Donna Karan New York has always been defined by two enduring muses: the woman and the city. One shapes the other. Together, they embody a spirit that is at once powerful and effortless, timeless and unmistakably modern.</div><div><br></div><div>The Fall 2026 campaign, photographed by Mert Alas, and starring Kendall Jenner, further strengthens this bond. For the first time since the brand&#039;s relaunch, the campaign unfolds across iconic New York City locations, where the city&#039;s energy, texture, and light become an extension of the collection itself.</div><div><br></div><div>The visual style references a late 1980s Donna Karan campaign photographed by Dennis Piel, that featured Rosemary McGrotha - expressing her inner thoughts inside a limousine coming into New York. That film, which felt remarkably ahead of its time, inspires this latest concept, where Kendall imagines she has New York City entirely to herself.</div><div><br></div><div>With the INXS track, Never Tear Us Apart, each scene is captured with cinematic richness. Appearing inside and outside the car, Kendall balances edge with glamour, revealing a femininity that is both direct and unmistakably Donna Karan. She describes what makes the city so compelling, for it is here that the possibilities seem limitless.</div><div><br></div><div>"Donna Karan has always embodied confidence and effortless sophistication, qualities I really connect with. Being a part of the Fall 2026 campaign felt like celebrating the energy of New York and a woman who knows her style and embraces who she is," says Kendall Jenner.</div><div><br></div><div>Kendall spotlights the iconic bodysuit from the Donna Karan archives, reimagined for Fall 2026, alongside key looks from the collection, including a draped wool jersey jacket and skirt layered beneath a leather coat and a richly tailored velvet suit. Several of these looks are defined by a seasonal shade of black cherry: more luscious than oxblood and more intriguing than classic black. Kendall also wears a stylized aviator jacket and skirt in deep, espresso brown, as well as a full-length sequin dress that gives off a sultry shimmer. The looks are completed with the Cashmere Tote in Chocolate Suede and the Black Cherry Leno bag, sculptural gold accessories, and eyewear.</div><div><br></div><div>In his recognizable style, Alas focuses on the individuality and modern spirit of Kendall, who conveys the chic sensibility of the season and the overarching spirit of Donna Karan New York.</div><div><br></div><div>The Donna Karan New York campaign launches today, September 2nd across all Donna Karan New York social channels, featuring Kendall Jenner. This powerful narrative will be amplified with a 360-degree approach, utilizing a diversified media mix of high-visibility digital platforms, striking print placements, and premium outdoor displays. The Fall 2026 Collection is available to shop now on DonnaKaran.com and select retailers globally.</div><div><br></div><div>Creative Direction by Trey Laird</div><div>Photography by Mert Alas</div><div>Styled by Jessica Diehl</div><div>Hair by Chris McMillan</div><div>Makeup by Mary Phillips</div><div>BTS by Adrian Martin and Natalie Paul</div><div><br></div><div>ABOUT DONNA KARAN NEW YORK</div><div><br></div><div>Donna Karan New York revolutionized women&#039;s fashion in 1984 with Seven Easy Pieces, a groundbreaking system that made dressing effortless, sophisticated, and empowering. Now under the ownership of G-III Apparel Group, Ltd. since 2016, the brand enters a new chapter with its 2024 relaunch. While staying true to its original vision, the iconic Donna Karan New York has evolved to meet the needs of the modern woman, offering designs that inspire confidence with timeless, versatile pieces that seamlessly integrate into daily life. With expanded distribution, Donna Karan New York continues to bring its signature style to a broader audience, resonating with women globally.</div><div><br></div><div>ABOUT G-III APPAREL GROUP, LTD.</div><div><br></div><div>G-III Apparel Group, Ltd. is a global fashion leader with expertise in design, sourcing, distribution, and marketing. The Company owns and licenses a portfolio of more than 30 preeminent brands, each differentiated by unique brand propositions, product categories, and consumer touchpoints. G-III owns ten iconic brands, including DKNY, Donna Karan, Karl Lagerfeld, Sonia Rykiel, and Vilebrequin, and licenses over 20 of the most sought-after names in global fashion, including Levi&#039;s, Halston, Champion, Converse, Cole Haan, BCBG, French Connection, Calvin Klein, Tommy Hilfiger, Starter, as well as major sports leagues such as the NFL, NBA, NHL and MLB, among others.</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div></div> ]]></description>
<pubDate>Fri, 04 Sep 2026 06:45:00 +0700</pubDate>
</item>
<item>
<title>Founder Group Targets Malaysia&#039;s RM13 - 15 billion (approximately US$3.2 billion and US$3.7 billion) LSS6 National Solar</title>
<link>https://antaranusa.com/antaranusa-business/Founder-Group-Targets-Malaysia--039-s-RM13---15-billion--approximately-US-3-2-billion-and-US-3-7-billion--LSS6-National-Solar</link>
<description><![CDATA[<img src=https://antaranusa.com/photo/berita/dir092026/7127_Founder-Group-Targets-Malaysia--039-s-RM13---15-billion--approximately-US-3-2-billion-and-US-3-7-billion--LSS6-National-Solar.jpg border=0 hspace=5 align=left width=350 />  <div><br></div><div><div>Programme, Positioning for Multi-Year Order Book Growth Through 2029</div><div><br></div><div>KUALA LUMPUR, Malaysia, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Founder Group Limited (&#039Founder Group&#039; or the &#039Company&#039;) (NASDAQ: FGL) announced today that its subsidiary, Founder Energy Sdn. Bhd. (&#039Founder Energy&#039;), is actively tendering for projects under the Large-Scale Solar 6 ("LSS6") programme, Malaysia&#039;s largest-ever utility-scale solar tender.</div><div><br></div><div>The Company believes LSS6 represents a multi-year growth opportunity that could progressively expand its order book from the current tender period through the programme&#039;s targeted commercial operation date of December 31, 2029.</div><div><br></div><div>LSS6: Malaysia&#039;s Largest Utility-Scale Solar Programme</div><div><br></div><div>The Ministry of Energy Transition and Water Transformation (PETRA) launched LSS6 in July 2026, offering a total quota of 2,500 megawatts (MW) of solar capacity paired with 1,250MW of battery energy storage system (BESS) capacity, together with a further 150MW of solar capacity reserved for Bumiputera companies in Peninsular Malaysia. PETRA has stated that the programme is expected to attract between RM13 billion and RM15 billion (between US$3.2 billion and US$3.7 billion) in private investment, with projects to be commissioned in phases and targeted to reach full commercial operation by December 31, 2029. As compared to previous LSS rounds, LSS6 is also the first LSS round to mandate hybrid solar-BESS development, and it translates into an engineering, procurement, construction and commissioning (EPCC) opportunity of comparable scale, the addressable market that Founder Energy is now tendering into.</div><div><br></div><div>Founder Energy&#039;s Service Capabilities: Full-Suite EPCC & AI-Powered O&M</div><div><br></div><div>Founder Energy&#039;s end-to-end EPCC capability is well matched to the LSS6&#039;s scale, phased build-out, and multi-year construction runway, and the Company expects to see its order book growth progressively between now and the programme&#039;s targeted commercial operation date as tender awards and construction packages are officially commerced.</div><div><br></div><div>Since inception, Founder Energy has been involved in over 70 solar EPCC and sub-EPCC projects across Peninsular Malaysia, spanning most of the phases of the government&#039;s LSS programme since 2016, the Corporate Green Power Programme (CGPP), independent power producer (IPP) and Self-Consumption (SELCO) schemes, floating solar, and commercial and industrial (C&I) rooftop installations. Across its completed and on-going project base, Founder Energy has delivered work on facilities representing a combined total of over 1GWp of DC solar capacity, with an aggregate contract value of approximately RM520 million (US$128.6 million). Founder Group&#039;s demonstrated ability to secure both direct EPCC awards, and sub-EPCC packages alongside established industry participants is a core competitive strength that it intends to leverage in pursuing LSS6 opportunities.</div><div><br></div><div>Beyond EPCC delivery, Founder Group also provides long-term asset lifecycle management. The Company integrates the proprietary AI-driven Operations & Maintenance (O&M) technologies. With LSS6 the first LSS round to mandate integrated BESS and a 2029 commercial operation horizon spanning decades of subsequent operation, the Company believes this O&M capability also positions it to capture recurring, long duration revenue that extends well beyond the construction phase into long-term asset management, complementing the project-based EPCC order book with a recurring, longer tail revenue stream.</div><div><br></div><div>CEO Commentary</div><div><br></div><div>"LSS6 is the largest solar tender Malaysia has ever launched, and it plays directly to our strengths as a full-capability EPCC provider. We are already active in the market, and our existing collaboration with leading Malaysian and International Solar companies who are best positioned to win LSS6 packages will directly benefit us through awards to be made over the next four years. Between these four years until LSS6 commissioned at the end of 2029, we are going to see us replenish our order book with new contracts and grow the business substantially," said Lee Seng Chi, chief executive officer of Founder Group Limited.</div><div><br></div><div>About Founder Group Limited</div><div><br></div><div>Founder Group Limited is a pure-play, end-to-end EPCC solutions provider for solar PV facilities in Malaysia. The company&#039;s primary focus is on two key segments: large-scale solar projects and commercial and industrial (C&I) solar projects. The company&#039;s mission is to provide customers with innovative solar installation services, promote eco-friendly resources and achieve carbon neutrality.</div><div><br></div><div>For more information on the Company, please visit https://www.founderenergy.com.my/.</div><div><br></div><div>Safe Harbor Statement</div><div><br></div><div>This press release contains forward-looking statements that reflect our current expectations and views of future events. Known and unknown risks, uncertainties and other factors, including those listed under "Risk Factors" in the Company&#039;s filings with the U.S. Securities and Exchange Commission, may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. You can identify some of these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" or other similar expressions.</div><div><br></div><div>We have based these forward-looking statements largely on our current expectations and projections about future events that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements involve various risks and uncertainties. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. We qualify all of our forward-looking statements by these cautionary statements.</div><div><br></div><div>CONTACT INFORMATION:</div><div><br></div><div>For media queries, please contact:</div><div><br></div><div>Founder Group Limited</div><div>info@founderenergy.com.my</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div></div> ]]></description>
<pubDate>Thu, 03 Sep 2026 21:23:00 +0700</pubDate>
</item>
<item>
<title>A Previously Unattested Egyptian Title and a Face from Roman Egypt: TimeLine&#039;s 8 September Auction</title>
<link>https://antaranusa.com/antaranusa-business/A-Previously-Unattested-Egyptian-Title-and-a-Face-from-Roman-Egypt--TimeLine--039-s-8-September-Auction</link>
<description><![CDATA[<img src=https://antaranusa.com/photo/berita/dir092026/2614_A-Previously-Unattested-Egyptian-Title-and-a-Face-from-Roman-Egypt--TimeLine--039-s-8-September-Auction.jpg border=0 hspace=5 align=left width=350 />  <div><br></div><div><div>Day One, "Wonders of the Past", offers 405 lots, including a Fayum portrait, a Flemish St Martin and two Rajasthani celestial musicians</div><div><br></div><div>HARWICH, United Kingdom, Sept. 02, 2026 (GLOBE NEWSWIRE) -- A previously unattested Egyptian title, carved into a monument made for a son of Ramesses II, is among the highlights of TimeLine Auctions&#039; 8 September "Wonders of the Past" sale.</div><div><br></div><div>Carved in granite for Prince Parahirwenemef, son of Ramesses II and Nefertari, the base preserves the feet, sandals and toes of a kneeling royal statue (lot 16, 19th Dynasty, circa 1250 B.C., EUR40,000-60,000). Among the titles carved on the plinth is tpy n ms&#039;, "chief of troops" - a rank not previously attested. Egyptologist Paul Whelan is preparing a study.</div><div><br></div><div>A man in Roman Egypt sits for his portrait holding a glass of wine and wearing a garland of roses, a ring on his finger. The Fayum wooden portrait of a bearded man (lot 116, ?18,000-24,000) captures him at a moment of ease and ceremony. Published by Klaus Parlasca, it survives as a remarkably direct image of an individual from seventeen centuries ago.</div><div><br></div><div>Two gandharvas, celestial musicians from Rajasthan, are shown in red sandstone, one playing a stringed instrument and the other a drum (lot 247, 11th-12th century A.D., EUR20,000-30,000). Their carved hair, jewellery and eyelids retain a remarkable level of detail.</div><div><br></div><div>A 15th-century Flemish carver depicts St Martin on horseback, arm raised to divide his cloak and give part of it to the beggar below (lot 306, EUR20,000-30,000).</div><div><br></div><div>"Collecting is nothing new. In the 1st century B.C., Cicero wrote to a friend in Athens asking for more Greek sculpture for his villa. The objects we collect have always moved through other hands, other homes, other lives. Many have outlived the empires that made them.</div><div><br></div><div>"To collect is simply to take your turn holding something that was never meant to stay in one place forever. We are custodians, and only for a while." - Aaron Hammond</div><div><br></div><div>Auction: 8 September, 1pm BST / 8am ET. Further auctions: "Discover the Past", 9-11 September; Natural History and Philately, 12 September; Numismatics, 15-16 September. Bidding: absentee, telephone or live online. Enquiries: +44 (0) 1277 815121 / enquiries@timelineauctions.com</div><div><br></div><div>TimeLine Auctions is a British auction house specialising in antiquities, ancient art, coins and natural history.</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div></div> ]]></description>
<pubDate>Thu, 03 Sep 2026 21:16:00 +0700</pubDate>
</item>
<item>
<title>Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential</title>
<link>https://antaranusa.com/antaranusa-business/Teva-Announces-Positive-Topline-Results-from-Phase-2a-Study-in-Celiac-Disease-for-Its-Anti-IL-15-Antibody--Further-Validating-Its-Pipeline-in-a-Product-Potential</link>
<description><![CDATA[<img src=https://antaranusa.com/photo/berita/dir092026/9189_Teva-Announces-Positive-Topline-Results-from-Phase-2a-Study-in-Celiac-Disease-for-Its-Anti-IL-15-Antibody--Further-Validating-Its-Pipeline-in-a-Product-Potential.jpg border=0 hspace=5 align=left width=350 />  <div><p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";"><br>
*Teva-discovered TEVA&#039; 408, a novel anti-IL-15 monoclonal antibody,
demonstrated statistically significant and clinically meaningful prevention of
gluten-induced intestinal damage vs placebo following a single subcutaneous
dose.<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">*TEVA&#039; 408 was
well-tolerated with no safety signals observed to date.<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">*Together with the
vitiligo program, the celiac disease topline results further support TEVA&#039; 408
as a potential pipeline-in-a-product opportunity in multiple diseases.<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">&nbsp;</span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">Teva will hold an investor
call and live webcast today,<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">Wednesday, September 2,
2026, at 8:00 a.m. ET to discuss these data.<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">&nbsp;</span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">TEL AVIV, Israel, Sept.
02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and
TASE: TEVA) today announced positive topline results from an ongoing Phase 2a
study of TEVA&#039; 408, an investigational anti-interleukin-15 monoclonal antibody,
in adults with celiac disease. The study met its primary endpoint,
demonstrating statistically significant and clinically meaningful prevention of
gluten-induced intestinal damage versus placebo at week 8. TEVA&#039; 408 was
well-tolerated, with no safety signals observed to date.<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">&nbsp;</span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">"A strict
gluten-free diet has long been the only option for people living with celiac
disease. Yet, even with strict adherence to a gluten-free diet, many continue
to experience symptoms, intestinal damage and a significant impact on their
daily lives," said Eric Hughes, MD, PhD, Executive Vice President, Global
R&D and Chief Medical Officer at Teva. "These results underscore the
potential to move beyond managing gluten exposure and address celiac disease at
its biological source. They also strengthen our confidence in targeting the
IL-15 pathway as an approach to reducing immune-driven intestinal damage."<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">&nbsp;</span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">The ongoing randomized,
placebo-controlled study enrolled 50 adult participants with celiac disease on
a gluten-free diet (GFD) with minimal intestinal damage at baseline as measured
by the villous height-to-crypt depth ratio (Vh:Cd &#8805;2.0) and symptoms. Two weeks
after receiving a single dose of TEVA&#039; 408, participants began a six-week daily
gluten challenge (GC). The study assessed biopsy-based measures of intestinal
damage and inflammation along with patient-reported symptoms. At week 8 (the
end of the GC) TEVA&#039; 408:<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">&nbsp;</span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">Showed statistically significant
and clinically meaningful prevention of gluten-induced intestinal damage versus
placebo, as measured by the trial&#039;s primary endpoint of Vh:Cd ratio with a
least squares (LS) mean change from baseline of -0.43 compared with -0.88 for
placebo (treatment difference of 0.45, 95% CI: (0.06, 0.84), p<0.05).<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">Showed a favorable
effect on intestinal inflammation as measured by density of intraepithelial
lymphocytes (IELs) compared with placebo; the LS Mean change from baseline in
the density of IELs, was an increase of 27.60 for placebo compared to 0.37 for TEVA&#039;
408 treated participants (treatment difference of -27.23, 95% CI: (-39.67,
-14.79)).<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">Demonstrated lower GI
symptom scores versus placebo, as assessed using the Celiac Disease Symptom
Diary (CDSD), a patient-reported outcome (PRO).<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">Was well-tolerated with
no emerging safety signals.<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">&nbsp;</span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">Additional analyses from
the ongoing Phase 2a study are underway. Teva plans to present further data
from the study at a future scientific meeting.<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">&nbsp;</span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">Teva Investor Call<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">Teva will hold an
investor call and live webcast today, Wednesday, September 2, 2026, at 8:00
a.m. ET/ 2:00 p.m. CET to discuss these data. To participate, please register
in advance here. To access a live webcast of the presentation, visit Teva&#039;s
Investor Relations website. An archived version of the webcast will be
available 24 hours after the end of the live discussion.<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">&nbsp;</span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">About TEVA&#039; 408<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">TEVA&#039; 408, discovered by
Teva, is an investigational human monoclonal antibody designed to inhibit
interleukin-15 (IL-15), a cytokine involved in immune-mediated pathways. TEVA&#039;
408 has a high affinity and potency (in vitro) with a prolonged half-life that
supports the potential for convenient subcutaneous dosing.<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">&nbsp;</span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">TEVA&#039; 408 is being
studied as a potential therapy for celiac disease in a Phase 2a study and was
granted Fast Track designation in that indication by the U.S. FDA in May 2025.
By blocking IL-15 activity, TEVA&#039; 408 aims to reduce the IL-15-driven
intestinal inflammation and damage that are characteristic of celiac disease.<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">&nbsp;</span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">TEVA&#039; 408 is also being
evaluated in a Phase 1b study as a treatment for vitiligo. Following
encouraging results from the ongoing Phase 1b study in vitiligo, Teva is
advancing the investigational asset into a Phase 2b study in vitiligo. By
blocking IL-15 activity, TEVA&#039; 408 aims to reduce the immune-mediated
destruction of melanocytes (pigment-producing cells) resulting in white patches
on the skin characteristic of vitiligo.<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">&nbsp;</span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">Teva entered a strategic
funding agreement with Royalty Pharma in January 2026. Under the agreement,
Teva is eligible to receive up to $500 million to accelerate the clinical
development of TEVA&#039; 408. If approved and launched, Teva will pay a milestone
to Royalty Pharma and a royalty on worldwide net sales of TEVA&#039; 408.<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">&nbsp;</span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">About Celiac Disease<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">Celiac disease is a
serious autoimmune disease in which exposure to gluten triggers an immune
response that damages the small intestine. It affects approximately 1% of the
global population, or more than three million people in the U.S. alone,
although many individuals remain undiagnosed. Celiac disease can cause chronic
digestive symptoms, fatigue, nutrient deficiencies, and other health
complications that can significantly impact daily life.<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">&nbsp;</span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">There are currently no
approved therapies for celiac disease. A strict gluten-free diet (GFD) remains
the standard of care, yet even with careful adherence, patients may continue to
experience symptoms, reduced quality of life, and ongoing intestinal
inflammation or damage due to inadvertent gluten exposure. For people living
with celiac disease, managing the condition often requires constant vigilance
around meals, travel, work, and social activities, creating significant daily
burden. The limitations of current management approaches underscore the need
for therapies that address the underlying drivers of disease and improve
outcomes for patients.<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">&nbsp;</span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">About Teva<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">Teva Pharmaceutical
Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative
biopharmaceutical company, enabled by a world-class generics business. For over
120 years, Teva&#039;s commitment to bettering health has never wavered. From
innovating in the fields of neuroscience and immunology to providing complex
generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated
to addressing patients&#039; needs, now and in the future. At Teva, We Are All In
For Better Health. To learn more about how, visit www.tevapharm.com.<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">&nbsp;</span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">Cautionary Note
Regarding Forward-Looking Statements<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">This press release
contains forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, which are based on management&#039;s
current beliefs and expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future results,
performance or achievements to differ significantly from that expressed or
implied by such forward-looking statements. You can identify these
forward-looking statements by the use of words such as "should,"
"expect," "anticipate," "estimate,"
"target," "may," "intend," "plan,"
"believe" and other words and terms of similar meaning and expression
in connection with any discussion of future operating or financial performance.
Important factors that could cause or contribute to such differences include
risks relating to: our ability to successfully develop and commercialize
TEV-&#039;408 for the treatment of celiac disease and for the treatment of vitiligo;
our ability to successfully compete in the marketplace, including our ability
to develop and commercialize additional pharmaceutical products; our ability to
successfully execute on our Pivot to Growth strategy, including to expand our
innovative and biosimilar medicines pipeline and profitably commercialize our Innovative
medicines and biosimilar portfolio, whether organically or through business
development; and other factors discussed in our Quarterly Report on Form 10-Q
for the second quarter of 2026 and in our Annual Report on Form 10-K for the
year ended December 31, 2025, including in the sections captioned "Risk
Factors," and "Forward-Looking Statements." Forward-looking
statements speak only as of the date on which they are made, and we assume no
obligation to update or revise any forward-looking statements or other
information contained herein, whether as a result of new information, future
events or otherwise. You are cautioned not to put undue reliance on these
forward-looking statements.<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">&nbsp;</span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">Teva Media Inquiries:
TevaCommunicationsNorthAmerica@tevapharm.com<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">Teva Investor Relations
Inquiries: TevaIR@Tevapharm.com<o:p></o:p></span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">&nbsp;</span></p>

<p class="MsoNormal" style="margin-bottom: 0.0001pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 10pt; font-family: Helvetica, "sans-serif";">Copyright 2026
GlobeNewswire, Inc.<o:p></o:p></span></p>

<p class="MsoNormal"><o:p>&nbsp;</o:p></p></div>   ]]></description>
<pubDate>Thu, 03 Sep 2026 21:05:00 +0700</pubDate>
</item>
<item>
<title>Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials</title>
<link>https://antaranusa.com/antaranusa-business/Fortrea-to-Acquire-Clinical-Pharmacology-Unit-and-Bioanalytical-Laboratory-Operations-from-Worldwide-Clinical-Trials</link>
<description><![CDATA[<img src=https://antaranusa.com/photo/berita/dir092026/3108_Fortrea-to-Acquire-Clinical-Pharmacology-Unit-and-Bioanalytical-Laboratory-Operations-from-Worldwide-Clinical-Trials.jpg border=0 hspace=5 align=left width=350 />  <div><br></div><div><div>Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea&#039;s early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets</div><div><br></div><div>Highlights</div><div><br></div><div>*Fortrea enters into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials</div><div>Includes a 60,000 sq. ft. GLP bioanalytical lab in Austin; a 200-bed GCP-compliant clinical pharmacology unit in San Antonio; and a biospecimen storage facility in Pflugerville, Texas</div><div>*Enables integrated execution of early-phase studies with large and small molecule bioanalytical capabilities, enhancing Fortrea&#039;s ability to deliver faster, more integrated early clinical development solutions for simple and complex clinical studies</div><div>*Strengthens Fortrea&#039;s end-to-end clinical development platform, supporting customers from first-in-human studies through Phase IV and post-approval evidence generation</div><div>*Supports Fortrea&#039;s growth strategy through expanded scientific capabilities, increased early clinical development capacity and enhanced ability to create long-term value for shareholders</div><div>*Supports Worldwide Clinical Trials&#039; existing rapid global growth across oncology, neuroscience, internal medicine, and rare disease</div><div>Provides continuity of operations, study delivery and customer support throughout the transition through a strategic alliance agreement between the companies</div><div><br></div><div>DURHAM, N.C. and RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) and Worldwide Clinical Trials ("Worldwide"), leading global contract research organizations (CROs), today announced that they have signed a definitive agreement under which Fortrea will acquire Worldwide&#039;s Early Phase Services division ("Early Phase"), consisting of its Clinical Pharmacology Unit (CPU) and Bioanalytical Laboratory operations.</div><div><br></div><div>The acquisition further enhances Fortrea&#039;s position as a leading global clinical development partner, strengthening the front end of its development platform supporting customers across Phases I-IV. Worldwide will continue to support existing and future Phase I studies through its broader clinical development capabilities.</div><div><br></div><div>The Early Phase business provides integrated early-phase clinical development and bioanalytical services supporting drug candidates from early development through later-stage clinical research. The business includes a Good Laboratory Practice (GLP)-compliant bioanalytical laboratory in Austin, Texas; a 200-bed Good Clinical Practice (GCP)-compliant clinical pharmacology unit in San Antonio, Texas; and a biospecimen storage facility in Pflugerville, Texas-enabling coordinated execution of complex early-phase studies with operational delivery services and reducing operational handoffs between clinical and bioanalytical functions, providing customers with a more streamlined path from first-in-human through proof-of-concept studies.</div><div><br></div><div>The acquisition complements Fortrea&#039;s Clinical Pharmacology Services business and existing early phase capabilities by adding in-house large and small molecule bioanalytical capabilities and expanding its North American clinical research unit footprint. The addition of dedicated bioanalytical capabilities will enable Fortrea to improve turnaround times and deliver both simple and complex, integrated clinical development solutions. The combined platform will offer customers greater flexibility for complex and larger participant studies, broader access to distinct volunteer populations and expanded bedspace capacity across Fortrea&#039;s early development network.</div><div><br></div><div>The agreement enables Worldwide to continue to provide core healthy volunteer study capabilities globally through its external site network, ensuring sponsors have access to the expertise and services needed across all phases of development, while accelerating investment within its rapidly growing late-stage business across therapeutic expertise, technology, geographic expansion and long-term growth initiatives.&nbsp;</div><div><br></div><div>Together, the transaction positions both organizations to build on their respective strengths while continuing to support sponsors across the drug development lifecycle.</div><div><br></div><div>"Fortrea is making an important investment in early clinical development as part of our end-to-end clinical development platform supporting customers from first-in-human studies through Phase IV and post-approval evidence generation. We believe this acquisition strengthens our ability to create long-term value for shareholders while expanding the capabilities and capacity we provide to customers, volunteers and the patients we ultimately serve," said Anshul Thakral, CEO of Fortrea. "By bringing together complementary bioanalytical and clinical research offerings, we will enable a more seamless development experience for customers, broaden our scientific and operational capabilities and support studies of greater scale, complexity and scientific sophistication across a wider range of therapeutic needs. While these capabilities strengthen our integrated early development offering, they also enhance our ability to provide a more connected development experience to help sponsors advance their assets from early development through pivotal studies into post-approval evidence generation, bringing life-changing treatments to patients faster."</div><div><br></div><div>"Worldwide has built a respected Early Phase business, supported by a strong team and a reputation for scientific and operational excellence," said Alistair Macdonald, CEO of Worldwide. "This transaction allows us to focus our investments and support on our rapidly growing late-stage business across the oncology, neuroscience, internal medicine, and rare disease therapeutic areas. We are grateful for all that the Early Phase organization has accomplished and confident this creates new opportunities for our employees while enhancing our ability to invest in our long-term growth strategy-ensuring we continue delivering exceptional value to customers and patients around the world."</div><div><br></div><div>Fortrea and Worldwide intend to enter into a series of agreements to support continuity for customers, employees and ongoing programs. These agreements are intended to maintain project momentum, preserve specialized capabilities and provide a seamless customer experience during and after the transition.</div><div><br></div><div>Pursuant to a definitive agreement, Fortrea will acquire the Early Phase Services business from Worldwide in an all-cash transaction valued at approximately $45M. The transaction is expected to close pending approval of necessary regulatory and license requirements, as well as the parties entering into certain services agreements. Once the transaction is complete, Early Phase Services will become part of Fortrea&#039;s Clinical Pharmacology Services business unit. Both companies remain committed to providing a seamless transition for employees, customers, and volunteers.</div><div><br></div><div>Advisors</div><div>Barclays is serving as financial advisor to Fortrea, and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. is serving as its legal counsel. BroadOak Partners is serving as Worldwide&#039;s financial advisor and Greenberg Traurig, LLP is serving as its legal counsel.</div><div><br></div><div>About Fortrea</div><div>Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea&#039;s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in 100 countries is scaled to deliver focused and agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn, X and Bluesky.</div><div><br></div><div>About Worldwide Clinical Trials</div><div>Worldwide Clinical Trials (Worldwide) is a global CRO serving development-driven biopharmaceutical companies, with more than 4,500 full-time professionals operating across more than 70 countries. The company delivers therapeutically dedicated expertise in neuroscience, oncology, rare disease, and internal medicine, with comprehensive support across every development phase-from early-stage and first-in-human studies through Phase III registration trials.</div><div><br></div><div>The company&#039;s flexible service model-spanning full-service trial management to functional service partnerships through Worldwide Flex-is powered by a people-first, partnership-driven outsourcing approach that strengthens collaboration, enhances data transparency, and supports more informed decision-making. This provides sponsors with tailored, adaptable solutions that keep pace with the evolving demands of clinical research. Learn more at www.worldwide.com.</div><div><br></div><div>Cautionary Statement Regarding Forward-Looking Statements</div><div>This press release contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the anticipated benefits of the transaction, including future financial and operating performance, and the anticipated timing for completing the transaction. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "guidance," "expect," "assume," "anticipate," "intend," "plan," "forecast," "believe," "seek," "see," "will," "would," "target," similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</div><div><br></div><div>Actual results could differ materially from these forward looking statements due to a number of factors, including, but not limited to: satisfaction of the conditions precedent to consummation of the proposed acquisition of Early Phase Services from Worldwide Clinical Trials, including the ability to secure regulatory approvals, and the Company&#039;s ability to complete the transaction in a timely manner or at all;&#8239;the possibility that the transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; the parties&#039; ability to meet expectations regarding the accounting and tax treatments of the proposed transaction; and other factors described from time to time in documents that the Company files with the SEC.</div><div><br></div><div>For a further discussion of the risks relating to the Company&#039;s business, see the "Risk Factors" Section of the Company&#039;s Registration Statement on Form 10, as filed with the Securities and Exchange Commission (the "SEC"), as such factors may be amended or updated from time to time in the Company&#039;s subsequent periodic and other filings with the SEC, which are accessible on the SEC&#039;s website at <a href="http://www.sec.gov./">www.sec.gov.</a></div><div><br></div><div>These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included or incorporated by reference in this report and in the Company&#039;s filings with the SEC. All forward-looking statements are made only as of the date of this report and the Company does not undertake any obligation, other than as may be required by law, to update or revise any forward-looking statements to reflect future events or developments.&nbsp;</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div></div> ]]></description>
<pubDate>Thu, 03 Sep 2026 21:01:00 +0700</pubDate>
</item>
<item>
<title>Midea Redefines Home Care at IFA 2026 with &quot;Zoned Care Omni Clean&quot; Vision</title>
<link>https://antaranusa.com/antaranusa-business/Midea-Redefines-Home-Care-at-IFA-2026-with--quot-Zoned-Care-Omni-Clean-quot--Vision</link>
<description><![CDATA[<img src=https://antaranusa.com/photo/berita/dir092026/3425_Midea-Redefines-Home-Care-at-IFA-2026-with--quot-Zoned-Care-Omni-Clean-quot--Vision.jpg border=0 hspace=5 align=left width=350 />  <div><br></div><div><div>Following the success of Midea PortaSplit in Europe, Midea continues its locally focused approach to innovation. At IFA 2026, the company will showcase new laundry and floor care solutions specifically designed to meet the needs of modern European households.</div><div><br></div><div>BERLIN, GERMANY - Media OutReach Newswire - 2 September 2026 - Different textiles, delicate garments, pet hair, liquid spills and stubborn stains are making household cleaning increasingly complex. At IFA 2026, Midea will showcase new laundry and floor care solutions under the theme "Zoned Care. Omni Clean.", designed to address different cleaning needs in a more targeted, efficient and convenient way.</div><div><br></div><div>With "Zoned Care. Omni Clean.", Midea translates these diverse needs into two clearly defined solution areas. "Zoned Care" represents a more targeted and separated approach to caring for different textiles and laundry types, while "Omni Clean" focuses on delivering comprehensive floor cleaning across different types of dirt and mess. At IFA 2026, Midea will demonstrate how this approach is brought to life through new technologies, including the Midea Omni Trio multi-drum washing machine and the Midea AT8 Ultra wet-and-dry vacuum and floor cleaner.</div><div><br></div><div>IFA 2026 PRODUCT HIGHLIGHTS</div><div><br></div><div>Midea Omni Trio (Multi-Drum Washing Machine): Featuring three independent washing drums, each with its own Direct Drive motor and separate water flow system, the Omni Trio enables different textiles and laundry types to be washed simultaneously while remaining fully separated. Despite its multi-drum design, it maintains a compact standard height of 850 mm and can be installed without modifications to the existing laundry space. For added user comfort, the Omni Trio also carries the VDE "Low Noise" certification and, according to VDE, delivers low-noise performance that is 10% better than the requirements for Class A acoustic airborne noise emissions under EU Regulation 2019/2014.</div><div><br></div><div>Midea AT8 Ultra (Wet-and-Dry Vacuum & Floor Cleaner): Designed to address different floor-cleaning needs, the AT8 Ultra combines Easy Foam technology, 60?C hot water for stain removal, and an intelligent robotic arm for precise edge cleaning and the removal of residual water. The system is designed to reduce the need for additional cleaning detergent for up to one year.</div><div><br></div><div>With both new products, Midea is pursuing a shared approach: household appliances should adapt more closely to different lifestyles and cleaning needs - not the other way around. Through "Zoned Care. Omni Clean.", Midea brings together targeted laundry care solutions with comprehensive floor-cleaning technologies.</div><div><br></div><div>Visitors to IFA 2026 will be able to experience the new products and technologies live at the Midea booth and learn more about the innovations behind them.</div><div><br></div><div>Hashtag: #Midea</div><div><br></div><div>ABOUT MIDEA & MIDEA GROUP</div><div>Midea is a global technology company specializing in smart home appliances, climate solutions and floor care technologies, with a focus on user-centric design, energy efficiency and sustainable innovation.</div><div>The issuer is solely responsible for the content of this announcement.</div><div><br></div><div>Industry/Tags:</div><div><br></div><div>Advertising, Marketing & Public Relations&nbsp;ESG&nbsp;Retail&nbsp;Technology&nbsp;Business</div></div> ]]></description>
<pubDate>Thu, 03 Sep 2026 10:58:00 +0700</pubDate>
</item>
<item>
<title>MyRepublic launches Hyperpeer, a Game Acceleration Service for Singapore and Malaysia</title>
<link>https://antaranusa.com/antaranusa-business/MyRepublic-launches-Hyperpeer--a-Game-Acceleration-Service-for-Singapore-and-Malaysia</link>
<description><![CDATA[<img src=https://antaranusa.com/photo/berita/dir092026/7883_MyRepublic-launches-Hyperpeer--a-Game-Acceleration-Service-for-Singapore-and-Malaysia.jpg border=0 hspace=5 align=left width=350 />  <div><br></div><div><div>SINGAPORE - Media OutReach Newswire - 2 September 2026 - MyRepublic announced the launch of Hyperpeer, a Game Acceleration Service for gamers in Singapore and Malaysia. The service is open to gamers regardless of which internet service provider they use. Hyperpeer optimises gaming-related routing for supported online games, helping to deliver an enhanced gaming experience with up to 30% reduction in ping.</div><div><br></div><div>Hyperpeer, a Game Acceleration Service for gamers.</div><div>Hyperpeer, a Game Acceleration Service for gamers.</div><div><br></div><div>A 24-month subscription to Hyperpeer is also included with MyRepublic&#039;s GAMER+ Broadband Plans, further strengthening the company&#039;s commitment to meeting the increasing needs of the gaming community.</div><div><br></div><div>Hyperpeer</div><div><br></div><div>Available as a standalone subscription, Hyperpeer automatically optimises routing by selecting the shortest available route to the game server, helping deliver lower latency, packet loss and jitter. With its private network dedicated exclusively to gaming traffic and not shared with other bandwidth-intensive activities such as video streaming, large downloads or file transfers, the service is designed to ensure dedicated gaming performance without compromise.</div><div><br></div><div>Gamers can enjoy a seamless experience with one-click connection and automatic route optimisation by downloading a lightweight desktop application designed with low PC requirements in mind. Customers can also access round-the-clock assistance through Hyperpeer&#039;s dedicated 24/7 helpdesk.</div><div><br></div><div>Hyperpeer is available at an introductory price of S$6.90 per month (usual price: S$9.90 per month) for the first 100 customers. Following the launch, MyRepublic will continue to enhance the service with more supported games, new features, regular updates, network expansion and optimisation, and with more supported countries to be added in 2027.</div><div><br></div><div>Gamers are also welcome to request the games they would like to be included as part of upcoming enhancements. To do that, they can simply do so via the Hyperpeer website.</div><div><br></div><div>MyRepublic&#039;s GAMER+ Broadband Plans</div><div><br></div><div>Hyperpeer has also been added to MyRepublic&#039;s newly launched GAMER+ broadband plans, further enhancing the ultra-low latency gaming experience enabled by the current custom network routing of optimised routes MyRepublic GAMER broadband users are familiar with.</div><div><br></div><div>This follows the recent launch of the Dreamcore x MyRepublic RTX5060Ti Gaming PC, the ASUS T1 RTX 5070 Graphics Card Bundle, and a refresh of gaming routers, as MyRepublic continues to enhance its propositions to better serve the gaming community.</div><div><br></div><div>"With the launch of Hyperpeer and our new GAMER+ proposition, we are redefining the gaming connectivity landscape. While we continue to enhance our GAMER plans, we also recognise that gamers deserve great experiences regardless of who their internet provider is. That&#039;s why we&#039;re introducing solutions that benefit gamers across Singapore, including Malaysia, and eventually the wider region. Our ambition is to make a better gaming experiences more accessible and continue supporting the community we&#039;ve proudly championed since day one." said Lawrence Chan, Managing Director and Chief AI Officer, MyRepublic.</div><div><br></div><div>Get started</div><div><br></div><div>New users can activate a complimentary 7-day free trial before selecting a subscription plan with an early bird launch special promo currently ongoing.</div><div><br></div><div>Visit https://hyperpeer.net to create an account, start your free trial, and discover the MyRepublic gaming experience.</div><div>https://myrepublic.net/sg/</div><div>https://www.linkedin.com/company/myrepublic</div><div>https://x.com/myrepublic</div><div>https://www.facebook.com/MyRepublicSG/</div><div>https://www.instagram.com/myrepublicsg/</div><div>Hashtag: #Hyperpeer #MyRepublic #Gaming #GameAcceleration #GamingConnectivity #OnlineGaming #Gamer</div><div><br></div><div><span style="font-size: 14px;">MyRepublic Broadband Pte Ltd</span></div><div>MyRepublic Broadband Pte Ltd is a Singapore-based telecommunications provider delivering high-speed broadband, managed services, and connectivity solutions to consumers and businesses. MyRepublic serves the SME segment with business internet plans, managed IT services, and cybersecurity solutions designed for growing companies. For more information, visit https://myrepublic.net/sg/.</div><div>The issuer is solely responsible for the content of this announcement.</div><div><br></div><div>Industry/Tags:&nbsp;<span style="font-size: 14px;">Entertainment&nbsp;</span><span style="font-size: 14px;">Business&nbsp;</span><span style="font-size: 14px;">Travel & Leisure&nbsp;</span><span style="font-size: 14px;">Retail,&nbsp;</span><span style="font-size: 14px;">Esports,&nbsp;</span><span style="font-size: 14px;">Technology,&nbsp;</span><span style="font-size: 14px;">Lifestyle</span></div></div> ]]></description>
<pubDate>Thu, 03 Sep 2026 10:54:00 +0700</pubDate>
</item>
<item>
<title>The Mineral Boutique Limited Welcomes CCS Clarification and Reaffirms Asia Growth Strategy</title>
<link>https://antaranusa.com/antaranusa-business/The-Mineral-Boutique-Limited-Welcomes-CCS-Clarification-and-Reaffirms-Asia-Growth-Strategy</link>
<description><![CDATA[<img src=https://antaranusa.com/photo/berita/dir092026/1816_The-Mineral-Boutique-Limited-Welcomes-CCS-Clarification-and-Reaffirms-Asia-Growth-Strategy.jpg border=0 hspace=5 align=left width=350 />  <div><br></div><div><div>The Competition and Consumer Commission of Singapore clarified that The Mineral Boutique Limited was not part of the DNA Brands investigation, as the Hong Kong beauty and wellness company looks to its next phase of growth across Asia</div><div><br></div><div>HONG KONG SAR - Media OutReach Newswire - 2 September 2026 - The Mineral Boutique Limited, the Hong Kong-registered owner of The Mineral Boutique brand and trademarks, welcomes the clarification issued by the Competition and Consumer Commission of Singapore ("CCS") concerning its investigation into DNA Brands Co Pte Ltd.</div><div><br></div><div>The Mineral Boutique Limited Welcomes CCS Clarification and Reaffirms Asia Growth Strategy</div><div>In its clarification of 11 August 2026, CCS confirmed that references to The Mineral Boutique concerned specific Singapore outlets operated by DNA Brands, and that The Mineral Boutique Limited was not subject to the investigation. This distinction has subsequently been reflected in updated media reporting.</div><div><br></div><div>CCS stated:</div><div><br></div><div>"The Mineral Boutique Limited, and any outlets other than those named above trading under The Mineral Boutique brand trademarks, were not subject to this investigation."</div><div><br></div><div>The distinction is important: operating particular retail outlets under a brand name is separate from ownership or management of the underlying brand.</div><div><br></div><div>Because the relevant Singapore outlets traded under The Mineral Boutique name, earlier public reporting sometimes conflated operation of those particular outlets with ownership or management of the underlying brand. The CCS clarification allows that distinction to be reflected accurately in the continuing public record.</div><div><br></div><div>The Mineral Boutique Limited supports the continued identification of the relevant Singapore outlets where necessary to assist consumers and the CCS refund process. The company has asked publishers only to ensure that the continuing public record accurately distinguishes those DNA Brands-operated outlets from The Mineral Boutique Limited and its wider business.</div><div><br></div><div>CCS&#039;s refund scheme identifies the relevant Singapore outlets at Jewel Changi Airport, NEX and Wheelock Place among the outlets operated by DNA Brands. Consumers who may be eligible for the refund scheme can continue to contact the Consumers Association of Singapore ("CASE") directly.</div><div><br></div><div>Building the Next Phase of The Mineral Boutique</div><div><br></div><div>With this distinction now reflected in the official record, The Mineral Boutique is focused on its next stage of development.</div><div><br></div><div>The Mineral Boutique is a beauty and wellness concept with an established retail and spa presence across Hong Kong and Macau. Its approach brings together mineral-powered skincare, professional treatments, advanced beauty technology and wellness within an integrated customer experience.</div><div><br></div><div>The brand has received consecutive recognition from Vogue Hong Kong, including Best Beauty Flash at the 2025 Vogue Hong Kong Beauty Awards and Best Anti-Aging Mask at the 2026 awards.</div><div><br></div><div>Kimmy Lee, Chief Commercial Officer of The Mineral Boutique Limited, said:</div><div><br></div><div>"The Mineral Boutique will continue to grow across Asia through a more holistic approach that connects skincare, advanced beauty technology, professional treatments and wellness.</div><div><br></div><div>"An upcoming collaboration with Paris-based 48 Collagen Caf? is one example of how we are extending the customer experience beyond traditional beauty retail.</div><div><br></div><div>"We remain focused on innovation, trusted partnerships and consistently high standards of service as we build the next chapter of The Mineral Boutique across the region."</div><div><br></div><div>The Mineral Boutique Limited will continue working constructively with media, partners and other stakeholders to ensure the public record remains accurate while advancing its long-term growth strategy across Asia.</div><div><br></div><div>https://themineralboutique.com</div><div>https://www.facebook.com/TheMineralBoutique/</div><div>https://www.instagram.com/themineralboutiqueofficial/</div><div>https://www.ccs.gov.sg/consumer-protection/legislation-and-guidelines/refund-scheme-for-affected-consumers-of-dna-brands/</div><div>Hashtag: #TheMineralBoutique</div><div><br></div><div>About The Mineral Boutique Limited</div><div>The Mineral Boutique Limited is a Hong Kong-registered company and owner of The Mineral Boutique brand and trademarks.</div><div><br></div><div>The Mineral Boutique combines premium skincare, professional treatments, advanced beauty technology and wellness experiences, with an established retail and spa presence across Hong Kong and Macau.</div><div><br></div><div>The issuer is solely responsible for the content of this announcement.</div><div><br></div><div>Industry/Tags:&nbsp;Advertising, Marketing & Public Relations,&nbsp;Business,&nbsp;Lifestyle,&nbsp;Beauty,&nbsp;Intellectual Property, Trademark & Patent</div><div><br></div></div> ]]></description>
<pubDate>Thu, 03 Sep 2026 10:50:00 +0700</pubDate>
</item>
<item>
<title>Midea to Showcase SpaceMaster Series with Graphene Technology at IFA 2026</title>
<link>https://antaranusa.com/antaranusa-business/Midea-to-Showcase-SpaceMaster-Series-with-Graphene-Technology-at-IFA-2026</link>
<description><![CDATA[<img src=https://antaranusa.com/photo/berita/dir092026/5183_Midea-to-Showcase-SpaceMaster-Series-with-Graphene-Technology-at-IFA-2026.jpg border=0 hspace=5 align=left width=350 />  <div><br></div><div><div>Next-generation built-in oven features 350?C pizza cooking, an 81-liter capacity and smart connectivity ahead of its planned global launch in 2027.</div><div><br></div><div>BERLIN, GERMANY - Media OutReach Newswire - 2 September 2026 - Midea will showcase its new SpaceMaster Series built-in oven at IFA 2026 in Berlin, offering an early look at its next generation of smart kitchen appliances ahead of a planned global market launch in 2027.</div><div><br></div><div>At the core of the SpaceMaster Series is Midea&#039;s Graphene Turbo Hot Air Technology, designed to deliver rapid and even heat distribution. Leveraging graphene&#039;s high thermal conductivity, the heating system responds in as little as 0.2 seconds, enabling precise temperature control while reducing preheating time.</div><div><br></div><div>The technology also supports a dedicated 350?C pizza program. Combined with the included refractory pizza stone, the high-temperature cooking mode is designed to produce crisp, stone-baked-style pizza at home.</div><div><br></div><div>Key features of the Midea SpaceMaster Series include:</div><div>Graphene Turbo Hot Air Technology: Rapid 0.2-second heating response for precise and energy-efficient cooking.</div><div>350?C Pizza Program: High-temperature cooking with a dedicated pizza stone for crisp, pizzeria-style results.</div><div>81-Liter Capacity: A spacious cavity supports simultaneous cooking across three levels with independent temperature control.</div><div>Smart and Easy-Care Design: Dual self-cleaning, A++ energy efficiency, Midea SmartHome App connectivity, and compatibility with Google Home and Amazon Alexa.</div><div>The 81-liter oven is designed for households preparing multiple dishes at once, while its multi-level cooking system enables different foods to be cooked simultaneously with individual temperature settings. A dual self-cleaning system simplifies maintenance, while connected controls provide additional flexibility for everyday use.</div><div><br></div><div>"Cooking at home has become more than a routine task for many consumers; it is increasingly part of how people experience quality, creativity and enjoyment in everyday life," said a Midea spokesperson. "With the SpaceMaster Series, we are combining advanced thermal technology with intuitive operation to make professional cooking capabilities, including 350?C pizza baking, more accessible in the home."</div><div><br></div><div>Hashtag: #Midea</div><div><br></div><div>About Midea & Midea MOA</div><div>Midea is a global technology group ranked No. 246 on the 2025 Fortune Global 500 and No. 39 among the world&#039;s most valuable technology brands in the Brand Finance Top 100 2026. Midea has ranked No. 1 globally in microwave appliances for 10 consecutive years (Euromonitor, 2016?2025). Its Microwave & Oven Appliance (MOA) division generated USD 3.05 billion in revenue in 2025.</div><div><br></div><div>Midea operates seven global R&D centers, holds more than 5,500 granted patents and serves markets in more than 160 countries and regions.</div><div><br></div><div>The issuer is solely responsible for the content of this announcement.</div><div><br></div><div>Industry/Tags:&nbsp;Advertising, Marketing & Public Relations,&nbsp;Technology,&nbsp;Business</div></div> ]]></description>
<pubDate>Thu, 03 Sep 2026 10:44:00 +0700</pubDate>
</item>
<item>
<title>*Macao Economic, Trade, and Tourism Investment Promotion Seminar Convened in Jakarta, Indonesia, ........</title>
<link>https://antaranusa.com/antaranusa-business/-Macao-Economic--Trade--and-Tourism-Investment-Promotion-Seminar-Convened-in-Jakarta--Indonesia----------</link>
<description><![CDATA[<img src=https://antaranusa.com/photo/berita/dir092026/9803_-Macao-Economic--Trade--and-Tourism-Investment-Promotion-Seminar-Convened-in-Jakarta--Indonesia----------.jpg border=0 hspace=5 align=left width=350 />  <div><br></div><div><div><div>*Macao Economic, Trade, and Tourism Investment Promotion Seminar Convened in Jakarta, Indonesia, Fostering Multi-Dimensional Cooperation to Jointly Explore New Opportunities Along the Silk Road</div><div><br></div></div><div>JAKARTA, INDONESIA - Media OutReach Newswire - 2 September 2026 - The Government of the Macao Special Administrative Region of the People&#039;s Republic of China convened a reception alongside the Macao Economic, Trade, and Tourism Investment Promotion Seminar in Jakarta, Indonesia, on September 1, to advance multi-domain cooperation between Macao and Indonesia at both governmental and non-governmental levels.</div><div><br></div><div>The event hosted over 120 business matching sessions, yielding more than 80 cooperation agreements across key sectors, including tourism, high-tech, healthcare, and conventions and exhibitions.</div><div><br></div><div>The event gathered over 350 distinguished guests, including Mr.Sam Hou Fai, Chief Executive of the Macao SAR; Susiwijono Moegiarso, Secretary of the Coordinating Ministry for Economic Affairs, Republic of Indonesia; and Wang Lutong, Chinese Ambassador to Indonesia. Also in attendance were members of the Macao SAR Government and entrepreneur delegations, representatives from the Chinese Embassy in Indonesia, and prominent figures from various sectors in Indonesia.</div><div><br></div><div>Mr.Sam Hou Fai stated that the implementation of China&#039;s 15th Five-Year Plan and the Macao SAR&#039;s 3rd Five -Year Plan will unlock cooperation opportunities between Macao and Indonesia. He noted that Indonesia is the birthplace of the "21st Century Maritime Silk Road," and both Macao and Indonesia are pivotal nodes along this route. Guided by the Belt and Road Initiative and the China-Indonesia Comprehensive Strategic Dialogue mechanism, the friendly cooperative ties are poised to deepen further.</div><div><br></div><div>In the first half of this year, international visitor to Macao rose by 6% year-on-year, with approximately 88,000 Indonesian tourists-ranking among the top source markets in Southeast Asia. This highlights the close ties between Macao and Indonesia in people-to-people exchanges, trade, and tourism. The Macao SAR Government is committed to promoting exchanges at all levels. By leveraging Macao&#039;s role as a vital bridgehead for China&#039;s high-level opening-up and as a "precise connector," Macao aims to strengthen all-around, pragmatic cooperation in trade, investment, MICE, tourism, and cultural exchanges, actively contributing to a China-Indonesia community with a shared future.</div><div><br></div><div>Edi Prio Pambudi, Deputy Minister for International Economic Cooperation of the Coordinating Ministry for Economic Affairs of Indonesia, stated in his speech that under the "One Country, Two Systems" principle, Macao has built an outstanding international reputation with its long-term stability, high degree of openness, and strong connectivity. As a vital hub for mutual learning between Chinese and Western civilizations, Macao has successfully gathered global talent, capital, and creativity. Indonesian sectors widely applaud and anticipate Macao&#039;s economic diversification.</div><div><br></div><div>He noted that close economic and cultural ties have driven Macao enterprises to invest in Indonesian projects like construction and transportation. In terms of tourism, Macao welcomed over 200,000 visitors from Indonesia last year, ranking Indonesia among Macao&#039;s top source markets in Southeast Asia. Indonesia&#039;s visa-free policy for Macao SAR passport holders will further facilitate mutual exchanges. Looking ahead, Indonesia and Macao share vast potential for cooperation in Halal products, Traditional Chinese Medicine (TCM), and connectivity.</div><div><br></div><div>The issuer is solely responsible for the content of this announcement.</div><div><br></div><div>Hashtags: #MacaoEconomicTradeandTourismInvestmentPromotionSeminar</div></div> ]]></description>
<pubDate>Thu, 03 Sep 2026 10:39:00 +0700</pubDate>
</item>
<item>
<title>Turntide Axial Flux Motors and Inverters Propel Fering&#039;s Long-Range, Hybrid Vehicle</title>
<link>https://antaranusa.com/antaranusa-business/Turntide-Axial-Flux-Motors-and-Inverters-Propel-Fering--039-s-Long-Range--Hybrid-Vehicle</link>
<description><![CDATA[<img src=https://antaranusa.com/photo/berita/dir092026/1457_.jpg border=0 hspace=5 align=left width=350 />  <div><br></div><div><div>Axial flux technology gave Fering the flexibility to integrate a powerful electric drivetrain into its rugged platform built for extreme range, demanding environments.</div><div><br></div><div>Gateshead, U.K., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Turntide Technologies (Turntide), a global leader in electrification and hybridization solutions, announced that Fering, a manufacturer of rugged off-road vehicles, selected Turntide axial flux motors and inverters for its hybrid vehicle.</div><div><br></div><div>The compact size and high power density of the technology helped Fering develop a rugged vehicle designed for long range, off-road capability and flexible deployment across multiple sectors.</div><div><br></div><div>Fering&#039;s vehicle uses a parallel hybrid system designed to support demanding duty cycles while maximizing efficiency and range. The propulsion system had to fit within the vehicle&#039;s existing architecture without compromising performance or capability. Turntide supplied Fering with a complete electric propulsion package consisting of:</div><div><br></div><div>*Axial flux motor for traction</div><div>*A motor for power generation</div><div>*Inverters for motor control</div><div><br></div><div>Turntide&#039;s motors provided the power density Fering needed while minimizing the space required within the vehicle. Turntide&#039;s application engineering team also worked closely with Fering during vehicle integration and testing to support successful implementation.</div><div><br></div><div>"Fering&#039;s vehicle platform is a good example of how hybridization can extend electrification into demanding vehicle applications," said Brad Bell, chief commercial officer for Turntide. "The compact size and high performance of axial flux technology can help manufacturers integrate electric propulsion into existing vehicle platforms while delivering the performance and capability required for next-generation vehicles."</div><div><br></div><div>Fering evaluated several axial flux motor suppliers during development before selecting Turntide because of the performance and reliability of its motors and the support of its engineering team.</div><div><br></div><div>"It&#039;s a real pleasure to be working with Turntide Technologies," said Gareth Reece, chief commercial officer, Fering Technologies. "By bringing together Turntide&#039;s world-class electrification technology with Fering&#039;s innovative approach to extreme mobility, we&#039;re creating opportunities to deliver highly capable, efficient and resilient solutions for some of the world&#039;s most demanding environments. We look forward to building on this relationship and demonstrating what our combined technologies can achieve."</div><div><br></div><div>Learn more from the full case study.</div><div><br></div><div>About Turntide Technologies?</div><div><br></div><div>Turntide Technologies designs and manufactures best-in-class electric motors, power electronics and energy storage for anything that moves.</div><div><br></div><div>Turntide Technologies operates in North America, the U.K. and India and serves customers in global markets and industries including off highway automotive, commercial vehicles, rail, marine, light vehicles and premium automotive.</div><div><br></div><div>About Fering</div><div><br></div><div>Fering creates vehicles that enable people to operate independently, efficiently and with confidence in places where conventional platforms cannot perform.</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div></div>   ]]></description>
<pubDate>Thu, 03 Sep 2026 10:33:00 +0700</pubDate>
</item>
<item>
<title>Pacifica Hotels Menandatangani Perjanjian Waralaba dengan Marriott International untuk Membuka Westin Hokkaido Furano Resort</title>
<link>https://antaranusa.com/antaranusa-business/Pacifica-Hotels-Menandatangani-Perjanjian-Waralaba-dengan-Marriott-International-untuk-Membuka-Westin-Hokkaido-Furano-Resort</link>
<description><![CDATA[<img src=https://antaranusa.com/photo/berita/dir092026/3188_Pacifica-Hotels-Menandatangani-Perjanjian-Waralaba-dengan-Marriott-International-untuk-Membuka-Westin-Hokkaido-Furano-Resort.jpg border=0 hspace=5 align=left width=350 />  <div><br></div><div><div>TOKYO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Pacifica Hotels G.K. beserta anak perusahaannya, Furano Hospitality G.K., hari ini mengumumkan penandatanganan perjanjian waralaba dengan Marriott International untuk membuka Westin Hokkaido Furano Resort. Properti ini akan menjadi Westin Resort pertama di Jepang sekaligus hotel Westin pertama di Hokkaido.</div><div><br></div><div>Resor ini memiliki 195 kamar dan suite yang didesain dengan indah, sejumlah restoran, pemandian dalam dan luar ruangan, spa, serta beragam fasilitas lainnya untuk para tamu.</div><div><br></div><div>"Kami berharap Westin Furano dapat segera menjadi hotel terkemuka di Furano sekaligus turut meningkatkan daya tarik kawasan ini di kalangan wisatawan mancanegara," ujar Seth Sulkin, CEO Pacifica Hotels G.K. dan Furano Hospitality G.K. "Furano merupakan destinasi resor yang menawan sepanjang tahun. Kawasan ini populer pada musim panas berkat hamparan ladang lavendernya yang luas dan pada musim dingin karena salju lembutnya yang berkualitas tinggi."</div><div><br></div><div>Pembangunan hotel itu dimulai pada Agustus 2026 dan dijadwalkan akan dibuka pada musim panas 2029. Hotel ini hanya berjarak beberapa menit berjalan kaki dari Stasiun Gondola Kitanomine dan menawarkan pemandangan indah pegunungan di sekitarnya yang memanjakan mata para tamu. Pilihan kulinernya akan mencakup restoran Omakase dengan konsep konter serta restoran yang buka sepanjang hari, tempat tamu dapat menikmati aneka hidangan segar yang diolah dari hasil laut, daging, produk susu, dan sayuran melimpah khas Hokkaido.</div><div><br></div><div>Penandatanganan proyek ini menandai tonggak masuknya Pacifica Hotels ke bisnis pengelolaan hotel dan resor kelas atas premium. "Kami berkomitmen untuk membangun dan mengelola hotel-hotel berkualitas yang membuat tamu ingin menginap di sana," ujar Tn. Sulkin. "Kami melihat peluang yang sangat besar untuk membantu pengembangan Furano secara lebih lanjut sebagai destinasi internasional."</div><div><br></div><div>Tentang Pacifica Hotels G.K.: Pacifica merupakan operator pihak ketiga terkemuka di Jepang untuk hotel-hotel bermerek internasional. Perusahaan ini mengelola berbagai merek berdasarkan perjanjian waralaba dengan Marriott International dan IHG. Rekam jejak Pacifica mencakup pengelolaan hotel-hotel di bawah berbagai merek, seperti Moxy, Fairfield by Marriott, Courtyard by Marriott, City Express by Marriott, Garner by IHG, serta Holiday Inn & Suites.</div><div><br></div><div>Untuk informasi selengkapnya, silakan hubungi:</div><div><br></div><div>Tn. Akio Nakamura, Direktur Eksekutif, Pacifica Hotels G.K. nakamura@pacifica-cap.com</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div></div> ]]></description>
<pubDate>Thu, 03 Sep 2026 10:26:00 +0700</pubDate>
</item>
<item>
<title>KKR-Singtel Consortium Completes Acquisition of STTGDC; Company Launches Refreshed Global Brand for Next Phase of Growth</title>
<link>https://antaranusa.com/antaranusa-business/KKR-Singtel-Consortium-Completes-Acquisition-of-STTGDC--Company-Launches-Refreshed-Global-Brand-for-Next-Phase-of-Growth</link>
<description><![CDATA[<img src=https://antaranusa.com/photo/berita/dir092026/3037_KKR-Singtel-Consortium-Completes-Acquisition-of-STTGDC--Company-Launches-Refreshed-Global-Brand-for-Next-Phase-of-Growth.jpg border=0 hspace=5 align=left width=350 />  <div><br></div><div><div>Completion strengthens STTGDC&#039;s ability to scale AI-ready digital infrastructure, building on strong operating momentum while maintaining continuity of strategy, leadership and customer commitment</div><div><br></div><div>SINGAPORE - Media OutReach Newswire - 2 September 2026 - STTGDC today announced the completion of its acquisition by a KKR-led consortium comprising funds managed by global investment firm KKR and Singtel, and unveiled a refreshed global brand, marking the beginning of the company&#039;s next chapter as a global digital infrastructure platform.</div><div><br></div><div>The transaction strengthens STTGDC&#039;s ability to execute a strategy already in motion, with long-term capital, increased financial flexibility and the consortium&#039;s global infrastructure experience providing continued growth and momentum. Customers will continue to be served by the same leadership team, operating discipline and long-term commitment that have underpinned the company&#039;s growth for more than a decade.</div><div><br></div><div>Retaining the STTGDC name, the refreshed brand reflects the scale, capabilities and global platform the company has built over more than a decade. It is anchored in Built Ready, expressing STTGDC&#039;s focus on delivering the reliable, resilient and AI-ready infrastructure required by customers across Asia, the United Kingdom and Europe.</div><div><br></div><div>"Today marks the most important turning point in STTGDC&#039;s evolution since we founded the company more than 12 years ago," said Bruno Lopez, President and Group CEO of STTGDC. "The completion of this transaction signals the beginning of a new chapter for our company. We have spent over a decade building a global platform with the scale, capabilities and operating discipline needed to support the next generation of cloud and AI growth. With the KKR-Singtel consortium&#039;s investment, we have greater capacity to grow and execute at scale while remaining true to the values and customer commitment that have defined STTGDC from its inception. Our refreshed brand reflects both the company we have become and the responsibility we carry as digital infrastructure becomes increasingly critical to economies, businesses and communities. Built Ready is our commitment to delivering the critical infrastructure our customers need to grow with confidence, while building responsibly and sustaining the trust of governments, customers and communities."</div><div><br></div><div>STTGDC enters this phase with strong operating momentum and a substantial development pipeline. Since the end of 2025, operational capacity has increased by 25% to 780MW. In addition, contracted capacity has grown by 50% and annualised earnings before interest, taxes, depreciation, and amortisation (EBITDA) has risen by 30%[1], reflecting continued demand from hyperscalers, cloud service providers, AI customers and enterprises across its markets.</div><div><br></div><div>As AI changes the scale, density and complexity of data centre development, the industry&#039;s defining challenge is increasingly the ability to convert demand into delivered capacity. This requires more than capital or land. It depends on coordinated planning across power, cooling, design, supply chains, financing and local market conditions, together with the discipline to deliver and operate mission-critical infrastructure reliably.</div><div><br></div><div>STTGDC&#039;s growth strategy remains focused on markets where customer requirements, power availability, infrastructure readiness, policy alignment and long-term fundamentals support responsible development. With close to 2GW of powered land secured for assets under construction and pipeline development, the company is well positioned to convert customer demand into delivered capacity. Its global platform capabilities and local execution experience enable it to navigate the distinct operating conditions in each market.</div><div><br></div><div>This approach guides STTGDC&#039;s growth and investment across its global portfolio.</div><div><br></div><div>In India, STTGDC has 34 data centres across 10 cities and more than 613MW of IT capacity. The company is strategically scaling its IT load capacity to support the country&#039;s expanding digital economy.</div><div><br></div><div>In Indonesia, STTGDC has been expanding its Jakarta campus, advancing a development pipeline of more than 360MW of AI-ready IT capacity backed by secured power. Recent development milestones continue to strengthen the company&#039;s ability to support Indonesia&#039;s growing cloud, AI and digital infrastructure requirements.</div><div><br></div><div>Singapore remains strategically important. The selection of STTGDC to develop 50MW of sustainable, AI-ready data centre capacity will support Singapore&#039;s continued development as a trusted and resilient hub for AI, digital infrastructure and international connectivity, contributing to the country&#039;s strategic, economic and sustainability priorities.</div><div><br></div><div>Responsible growth will remain integral to STTGDC&#039;s business and operations. With 83.2% of electricity consumption across its operations sourced from renewable energy, STTGDC surpassed its 2028 carbon intensity reduction target three years ahead of schedule. Alongside its environmental commitments, the company works closely with governments, customers and communities to address local priorities and earn the trust that underpins its social licence to operate.</div><div><br></div><div>[1] For the period from December 2025 through June 2026</div><div><br></div><div>About STTGDC</div><div>STTGDC is a leading data centre platform enabling the cloud, AI and digital services that power how people live, work and connect. Headquartered in Singapore, the company operates across Asia and Europe, serving major hyperscalers, cloud service providers and enterprises. Built on trust and proven execution, STTGDC combines global scale, operational discipline and deep local expertise to deliver the resilient, scalable and sustainable infrastructure customers rely on to grow with confidence, unlock new possibilities and seize the opportunities ahead. For more information, visit www.sttgdc.com.</div><div><br></div><div>The issuer is solely responsible for the content of this announcement.</div></div> ]]></description>
<pubDate>Thu, 03 Sep 2026 10:21:00 +0700</pubDate>
</item>
<item>
<title>Two Masters, One Bottle, One Game: Charles Leclerc and Hikaru Nakamura Went Head-To-Head in a First-Of-Its-Kind Chivas Regal Showdown at Monza</title>
<link>https://antaranusa.com/antaranusa-business/Two-Masters--One-Bottle--One-Game--Charles-Leclerc-and-Hikaru-Nakamura-Went-Head-To-Head-in-a-First-Of-Its-Kind-Chivas-Regal-Showdown-at-Monza</link>
<description><![CDATA[<img src=https://antaranusa.com/photo/berita/dir092026/9350_Two-Masters--One-Bottle--One-Game--Charles-Leclerc-and-Hikaru-Nakamura-Went-Head-To-Head-in-a-First-Of-Its-Kind-Chivas-Regal-Showdown-at-Monza.jpg border=0 hspace=5 align=left width=350 />  <div><br></div><div><div>Charles Leclerc took on Chess Grandmaster Hikaru Nakamura in a high-stakes head-to-head at the Chivas Regal Arena of Mastery</div><div><br></div><div>MONZA, Italy, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ahead of the Italian Grand Prix in Monza, Charles Leclerc and Chess Grandmaster Hikaru Nakamura met in a high-stakes, first-of-its-kind showdown. Brought together by Chivas Regal, the two masters faced off before a live crowd in one of the year&#039;s most unexpected matchups.</div><div><br></div><div>The head-to-head marked the ultimate expression of two creations born from the same mindset: Chivas Regal 16 Year Old, Leclerc&#039;s debut co-created whisky, and SE!ZE, his bespoke chess-inspired game. Inspired by the belief that success comes from deliberate choices, both were designed around the same principle: every move matters.</div><div><br></div><div>On one side, Leclerc, whose vision shaped both the whisky and the game, and whose pursuit of mastery has never been confined to one world. On the other, Nakamura: one of the most formidable minds in chess. Two elite competitors, one board, the ultimate test.</div><div><br></div><div>From the bottle to the board, Chivas Regal 16 Year Old and SE!ZE share the same DNA. Drawing on sixteen carefully selected whiskies, each aged at least sixteen years, Chivas Regal 16 is built from deliberate choices, including Charles&#039; selection of Longmorn Single Malt, matured in sherry casks, as the whisky&#039;s signature component. SE!ZE applies this same thinking to gameplay, where every decision carries weight and nothing is left to chance. Both are a living tribute to the same belief: true mastery is never accidental.</div><div><br></div><div>The Chivas Regal Arena of Mastery buzzed with energy. Fans packed in to witness the live one-time-only showdown as two elite competitors from different disciplines challenged each other across a single board. Every move drew a reaction. Every decision landed with weight. This wasn&#039;t just a game. It was a live, charged demonstration of what mastery looks like when it has everything to prove.</div><div><br></div><div>The showdown demonstrated that the spirit behind Chivas Regal 16 Year Old extends far beyond the bottle. Co-created by Charles Leclerc and Master Blender Sandy Hyslop around the number that has defined him, the whisky reflects Leclerc&#039;s drive to constantly push further.</div><div><br></div><div>"I&#039;ve faced plenty of challenges in my career, but stepping into the Chivas Regal Arena of Mastery was something entirely different," said Charles Leclerc, Global Brand Ambassador, Chivas Regal. "The crowd, the arena, facing Hikaru, the energy was electric. SE!ZE and Chivas Regal 16 are built on the same idea: that every choice matters and nothing happens by accident. Facing one of the greatest strategic minds in the world at my own game brought that to life in a way I hadn&#039;t anticipated. That&#039;s what Chivas Regal and I are always pushing towards: moments that test you in ways you don&#039;t expect."</div><div><br></div><div>Livestreamed via Chivas Regal&#039;s YouTube, the showdown offered a rare glimpse of mastery beyond its usual arena - a contest where the real aim was to prove what it means to push into the unknown.</div><div><br></div><div>"I&#039;ve competed in front of big crowds before, but nothing quite like that," said Chess Grandmaster Hikaru Nakamura. "Charles and Chivas Regal built a game that keeps you on edge from the first move: fast, precise, with no margin for error and where every decision matters. That&#039;s the kind of challenge that reveals what you&#039;re really made of. True mastery isn&#039;t just about knowing the game, it&#039;s about how you handle the pressure when it counts."</div><div><br></div><div>Raise a glass to the pursuit of better. Chivas Regal 16 Year Old is available on Amazon with an RRP of ?64.00/$69.99. SE!ZE will be available to play digitally later this year. Sign up here.</div><div><br></div><div>Please enjoy Chivas Regal responsibly and never drink and drive.</div><div><br></div><div>About Chivas Regal:</div><div>Chivas Regal&#039;s spiritual home lies at Strathisla distillery in Scotland.&#8239;It exports its whisky and spirit drinks to more than 100 countries across the world. Chivas Regal sells more than 4.5&#8239;million&#8239;nine-litre&#8239;cases every year.</div><div><br></div><div>&nbsp;Founding brothers James and John Chivas pioneered the art of whisky blending in 19th century Scotland through a tireless work ethic and expressing a constant drive for excellence, bold entrepreneurial energy and community building.</div><div><br></div><div>Their values inspired the Chivas Regal ethos&#8239;&#039I Rise We Rise&#039;, a rallying cry for the next generation of spirits drinkers who elevate themselves and those around them, forging new paths to success and blending greatness with generosity.</div><div><br></div><div>Today, Chivas Regal brings this spirit to life through its long-standing association with global sports culture. The brand has recently expanded its strong commitment to sporting success as Team Partner of the Scuderia Ferrari HP team and as Official Whisky Partner of Arsenal FC.</div><div><br></div><div>Launched in 1909, Chivas Regal was the original luxury blended Scotch whisky. Chivas Regal has been integral to the growth of the Scotch whisky category worldwide - with a retail sales&#8239;value today&#8239;of over&#8239;2bn. The Chivas Regal range blends timeless classics with modern innovation and includes Chivas Regal 12, Chivas Regal&#8239;18&#8239;and Chivas Regal 25 as key products, and it has recently started expanding into spirit drink innovations.</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div></div> ]]></description>
<pubDate>Thu, 03 Sep 2026 10:16:00 +0700</pubDate>
</item>
<item>
<title>Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September</title>
<link>https://antaranusa.com/antaranusa-business/Teva-to-Present-at-Morgan-Stanley--J-P--Morgan-and-BofA-Investor-Conferences-in-September</link>
<description><![CDATA[<img src=https://antaranusa.com/photo/berita/dir092026/5345_Teva-to-Present-at-Morgan-Stanley--J-P--Morgan-and-BofA-Investor-Conferences-in-September.jpg border=0 hspace=5 align=left width=350 />  <div><br></div><div><div>TEL AVIV, Israel, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva&#039;s President and CEO, will present at three upcoming investor conferences in September as follows:</div><div><br></div><div>*Morgan Stanley 24th Annual Global Healthcare Conference</div><div>Monday, September 14, 2026, at 8:30 A.M. Eastern Time (ET)</div><div><br></div><div>*J.P. Morgan U.S. All Stars Conference&nbsp;</div><div>Tuesday, September 22, 2026, at 8:00 A.M. British Summer Time (3:00 A.M. ET)</div><div><br></div><div>*BofA Global Healthcare Conference 2026&nbsp;&nbsp;</div><div>Wednesday, September 23, 2026, at 10:55 A.M. British Summer Time (5:55 A.M. ET)</div><div><br></div><div>To access a live webcast of the presentation, visit Teva&#039;s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations.</div><div><br></div><div>An archived version of the webcast will be available within 24 hours after the end of the live discussion.</div><div><br></div><div>About Teva</div><div><br></div><div>Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva&#039;s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients&#039; needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.</div><div><br></div><div>Cautionary Note Regarding Forward-Looking Statements</div><div><br></div><div>This Document and the presentation at the conferences may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management&#039;s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as "should," "expect," "anticipate," "estimate," "target," "may," "project," "guidance," "intend," "plan," "believe" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance.</div><div><br></div><div>Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace, including our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and to profitably commercialize our innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned "Risk Factors," "Other Information" and "Forward Looking Statements."</div><div><br></div><div>Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div></div> ]]></description>
<pubDate>Thu, 03 Sep 2026 10:10:00 +0700</pubDate>
</item>
<item>
<title>WHP Global and G-III Apparel Group Complete Acquisition of Marc Jacobs</title>
<link>https://antaranusa.com/antaranusa-business/WHP-Global-and-G-III-Apparel-Group-Complete-Acquisition-of-Marc-Jacobs</link>
<description><![CDATA[<img src=https://antaranusa.com/photo/berita/dir092026/1764_WHP-Global-and-G-III-Apparel-Group-Complete-Acquisition-of-Marc-Jacobs.jpg border=0 hspace=5 align=left width=350 />  <div><br></div><div><div>NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- WHP Global and G-III Apparel Group, Ltd. (NasdaqGS: GIII) today announced the closing of the acquisition of the Marc Jacobs brand from LVMH. Concurrently, WHP Global and G-III formed their previously announced joint venture ("JV") to co-own the Marc Jacobs intellectual property and accelerate the global growth of one of fashion&#039;s most influential brands. At closing, G-III also acquired the Marc Jacobs operating business and entered into a long-term license with the JV.</div><div><br></div><div>The new JV is co-owned by WHP Global and G-III, with each party owning a 50% equity stake. WHP Global leads the JV, including global brand licensing, while G-III owns and leads the operating business including wholesale, retail and e-commerce, and provides support services to the JV. Marc Jacobs will continue in his role as Founder and Creative Director, ensuring continuity of the brand&#039;s creative vision, runway collections and fashion shows. Together, WHP Global, G-III and Marc Jacobs are focused on expanding the Marc Jacobs brand&#039;s global reach and unlocking new opportunities across markets and product categories.&nbsp;&nbsp;</div><div><br></div><div>"Marc Jacobs is a defining name in fashion, with powerful cultural relevance and global growth potential," said Yehuda Shmidman, Founder, Chairman and CEO of WHP Global. "We want to thank LVMH for its stewardship of this brand over nearly three decades and for being a trusted partner throughout this process. Together with G-III, we have created a powerful platform that combines best-in-class brand management with exceptional operating expertise."</div><div><br></div><div>"This closing marks an exciting new chapter for Marc Jacobs, a brand with a distinctive creative legacy and global reach," said Morris Goldfarb, Chairman and Chief Executive Officer of G-III Apparel Group. "G-III brings the scale and expertise to build and grow global brands, and we look forward to working with the Marc Jacobs team and WHP Global to protect what makes the brand special while supporting its continued growth worldwide."</div><div><br></div><div>Advisors</div><div><br></div><div>Morgan Stanley & Co. LLC served as financial advisor to WHP Global and Gibson Dunn served as legal advisor. Morgan Stanley Senior Funding, Inc. provided debt financing to support the acquisition.&nbsp;&nbsp;</div><div><br></div><div>UBS served as financial advisor to G-III, and Paul, Weiss, Rifkind, Wharton & Garrison served as legal advisor.</div><div><br></div><div>Barack Ferrazzano served as legal advisor to LVMH.</div><div><br></div><div>ABOUT MARC JACOBS</div><div><br></div><div>Marc Jacobs created Marc Jacobs International with Robert Duffy in 1984, basing the brand on two very simple concepts: a love of fashion and a commitment to quality. Finding the perfect balance between tradition and innovation, highlighting Jacobs&#039; exuberant creativity, the brand has become a driving force in the industry. Part of a generation that&#039;s conscious of the world around it, sensitive to humanitarianism and social entrepreneurship, Marc Jacobs has made its mark as rebellious, unpredictable, original, unique, and authentic all at the same time. Committed to the communities around them, Marc Jacobs International leads by example, supporting over 75 charities and organizations around the world.</div><div><br></div><div>ABOUT WHP GLOBAL</div><div><br></div><div>WHP Global (www.whp-global.com) is a leading brand management platform founded in 2019 to acquire and grow consumer brands. Its portfolio includes 16+ powerful brands across fashion, sports, and hardgoods, generating over $9.5 billion in annual retail sales across 80+ countries. Headquartered in New York with offices worldwide, WHP Global partners with more than 200 leading operators and drives strategic value through proprietary initiatives, including an internal A.I. Innovation Lab.</div><div><br></div><div>ABOUT G-III APPAREL GROUP, LTD.</div><div><br></div><div>G-III Apparel Group, Ltd. is a global fashion leader with expertise in design, sourcing, distribution, and marketing. The Company owns and licenses a portfolio of more than 30 preeminent brands, each differentiated by unique brand propositions, product categories, and consumer touchpoints. G-III owns ten iconic brands, including Marc Jacobs, DKNY, Donna Karan, Karl Lagerfeld, Sonia Rykiel, and Vilebrequin, and licenses over 20 of the most sought-after names in global fashion, including Calvin Klein, Tommy Hilfiger, Levi&#039;s, Halston, Champion, Converse, Cole Haan, BCBG, French Connection, Starter, as well as major sports leagues such as the NFL, NBA, NHL and MLB, among others.</div><div><br></div><div>This press release contains forward-looking statements. Statements that are not historical or current facts, including statements about beliefs and expectations, are "forward-looking statements" as that term is defined under the federal securities laws. Forward-looking statements are subject to risks, uncertainties and factors which include, but are not limited to, risks relating to the ability to realize the anticipated benefits of the acquisition of the Marc Jacobs business; risks relating to significant costs related to the acquisition; the expected financial and operating performance and future opportunities following the consummation of the acquisition; risks relating to the reliance on licensed product; reliance on foreign manufacturers; risk of doing business abroad; the current economic and credit environment risks; the nature of the apparel industry, including changing customer demand and tastes; risks of operating a retail business; customer concentration; seasonality; customer acceptance of new products; the impact of competitive products and pricing; dependence on existing management; and possible disruption from acquisitions, as well as other risks detailed in G-III&#039;s filings with the Securities and Exchange Commission. G-III assumes no obligation to update the information in this press release.</div><div><br></div><div>Copyright 2026 GlobeNewswire, Inc.</div></div> ]]></description>
<pubDate>Thu, 03 Sep 2026 09:02:00 +0700</pubDate>
</item></channel></rss>